Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.

IF 12.2 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Gut Microbes Pub Date : 2024-01-01 Epub Date: 2024-01-18 DOI:10.1080/19490976.2024.2304157
R Forlano, L Martinez-Gili, P Takis, J Miguens-Blanco, T Liu, E Triantafyllou, C Skinner, R Loomba, M Thursz, J R Marchesi, B H Mullish, P Manousou
{"title":"Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.","authors":"R Forlano, L Martinez-Gili, P Takis, J Miguens-Blanco, T Liu, E Triantafyllou, C Skinner, R Loomba, M Thursz, J R Marchesi, B H Mullish, P Manousou","doi":"10.1080/19490976.2024.2304157","DOIUrl":null,"url":null,"abstract":"<p><p>Aberration of the \"gut-liver axis\" contributes to the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we use multi-omics to analyze the gut microbiota composition and metabolic profile of patients with type-2 diabetes mellitus (T2DM). T2DM patients were screened for liver disease by blood tests, ultrasound, and liver stiffness measurements. Stool microbiota was analyzed by 16S rRNA gene sequencing; metabolomic profiling by Nuclear Magnetic Resonance spectroscopy and Ultra-High Performance-Mass Spectrometry. Microbiome and metabolic signatures were analyzed in the whole cohort and in matched subsets to identify signatures specific for steatosis (MASLD±) or fibrosis (Fibrosis±). Gut permeability was assessed <i>in-vitro</i> using monolayers of MDCK cells and trans-epithelial electric resistance (TEER). Cytokine profile was assessed in serum and stools.Overall, 285 patients were enrolled: 255 serum, 252 urine and 97 stool samples were analyzed. <i>Anaeroplasma</i> and <i>Escherichia/Shigella</i> ASVs were higher, while <i>Butyricicoccus</i> ASVs were lower in those with normal liver. In MASLD±, <i>Butyricicoccus</i> ASV was significantly higher in those with steatosis. In the Fibrosis±, <i>Butyricicoccus</i> ASV was significantly lower in those with fibrosis. Glycochenodeoxycholic acid-3-sulfate (G-UDCA-3S) appeared to be higher in MASLD with fibrosis. Fecal water from patients with MASLD and fibrosis caused the greatest drop in the TEER vs those with normal liver; this was reversed with protease inhibitors. Finally, fecal IL-13 was lower in MASLD with fibrosis. We identified microbiome signatures which were specific for steatosis and fibrosis and independent of other metabolic risk factors. Moreover, we conclude that protease-related gut permeability plays a role in those MASLD patients with fibrosis, and that disease progression is linked to a gut-liver axis which is at least partially independent of T2DM.</p>","PeriodicalId":12909,"journal":{"name":"Gut Microbes","volume":"16 1","pages":"2304157"},"PeriodicalIF":12.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798360/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut Microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19490976.2024.2304157","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aberration of the "gut-liver axis" contributes to the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we use multi-omics to analyze the gut microbiota composition and metabolic profile of patients with type-2 diabetes mellitus (T2DM). T2DM patients were screened for liver disease by blood tests, ultrasound, and liver stiffness measurements. Stool microbiota was analyzed by 16S rRNA gene sequencing; metabolomic profiling by Nuclear Magnetic Resonance spectroscopy and Ultra-High Performance-Mass Spectrometry. Microbiome and metabolic signatures were analyzed in the whole cohort and in matched subsets to identify signatures specific for steatosis (MASLD±) or fibrosis (Fibrosis±). Gut permeability was assessed in-vitro using monolayers of MDCK cells and trans-epithelial electric resistance (TEER). Cytokine profile was assessed in serum and stools.Overall, 285 patients were enrolled: 255 serum, 252 urine and 97 stool samples were analyzed. Anaeroplasma and Escherichia/Shigella ASVs were higher, while Butyricicoccus ASVs were lower in those with normal liver. In MASLD±, Butyricicoccus ASV was significantly higher in those with steatosis. In the Fibrosis±, Butyricicoccus ASV was significantly lower in those with fibrosis. Glycochenodeoxycholic acid-3-sulfate (G-UDCA-3S) appeared to be higher in MASLD with fibrosis. Fecal water from patients with MASLD and fibrosis caused the greatest drop in the TEER vs those with normal liver; this was reversed with protease inhibitors. Finally, fecal IL-13 was lower in MASLD with fibrosis. We identified microbiome signatures which were specific for steatosis and fibrosis and independent of other metabolic risk factors. Moreover, we conclude that protease-related gut permeability plays a role in those MASLD patients with fibrosis, and that disease progression is linked to a gut-liver axis which is at least partially independent of T2DM.

2 型糖尿病患者肠道屏障完整性和宿主微生物组相互作用的破坏是 MASLD 严重性的基础。
肠肝轴 "畸变是代谢功能障碍相关性脂肪性肝病(MASLD)发生和发展的原因之一。在这里,我们利用多组学分析了2型糖尿病(T2DM)患者的肠道微生物群组成和代谢概况。我们通过血液化验、超声波检查和肝脏硬度测量对 T2DM 患者进行了肝病筛查。粪便微生物群通过 16S rRNA 基因测序进行分析;代谢组学分析通过核磁共振波谱和超高效质谱仪进行。对整个队列和匹配子集的微生物组和代谢特征进行了分析,以确定脂肪变性(MASLD±)或纤维化(Fibrosis±)的特异性特征。利用 MDCK 细胞单层和跨上皮电阻(TEER)对体外肠道通透性进行了评估。对血清和粪便中的细胞因子谱进行了评估。总共有 285 名患者参与了研究:对 255 份血清样本、252 份尿液样本和 97 份粪便样本进行了分析。在肝功能正常的患者中,厌氧支原体和埃希氏/志贺氏菌 ASV 较高,而丁酸球菌 ASV 较低。在 MASLD±中,脂肪肝患者的丁酸球菌 ASV 明显较高。在纤维化±中,纤维化患者的丁酸球菌 ASV 明显较低。甘氨胆酸-3-硫酸盐(G-UDCA-3S)在伴有纤维化的 MASLD 中似乎更高。MASLD和肝纤维化患者的粪便水与正常肝脏患者的粪便水相比,TEER下降幅度最大;蛋白酶抑制剂可逆转这种情况。最后,纤维化的MASLD患者粪便中的IL-13含量较低。我们发现了特异于脂肪变性和肝纤维化的微生物组特征,并且与其他代谢风险因素无关。此外,我们还得出结论,蛋白酶相关的肠道通透性在纤维化的 MASLD 患者中起着一定的作用,而且疾病的进展与肠道-肝脏轴相关,至少部分与 T2DM 无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gut Microbes
Gut Microbes Medicine-Microbiology (medical)
CiteScore
18.20
自引率
3.30%
发文量
196
审稿时长
10 weeks
期刊介绍: The intestinal microbiota plays a crucial role in human physiology, influencing various aspects of health and disease such as nutrition, obesity, brain function, allergic responses, immunity, inflammatory bowel disease, irritable bowel syndrome, cancer development, cardiac disease, liver disease, and more. Gut Microbes serves as a platform for showcasing and discussing state-of-the-art research related to the microorganisms present in the intestine. The journal emphasizes mechanistic and cause-and-effect studies. Additionally, it has a counterpart, Gut Microbes Reports, which places a greater focus on emerging topics and comparative and incremental studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信